Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03630042
Title Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia (PembroWM)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London

Waldenstroem's macroglobulinemia


Pembrolizumab + Rituximab

Age Groups: adult | senior
Covered Countries

No variant requirements are available.